- |||||||||| ketoconazole / Generic mfg., letrozole / Generic mfg., erlotinib / Generic mfg.
Journal: New 1,2,3-Triazole/1,2,4-triazole Hybrids as Aromatase Inhibitors: Design, Synthesis, and Apoptotic Antiproliferative Activity. (Pubmed Central) - Oct 28, 2023 Pharmacovigilance studies are crucial for the early identification of potential ADRs and to better differentiate the toxicity profile of the different CDK4/6 inhibitors, particularly in a real-world setting. The antiproliferative activity of the new hybrids against four cancer cells was studied using Erlotinib as a control...Results revealed that compounds 6a and 6b were the most potent aromatase inhibitors, with IC50 values of 0.12
- |||||||||| Ibrance (palbociclib) / Pfizer
Preclinical, Journal: In Vitro microRNA Expression Profile Alterations under CDK4/6 Therapy in Breast Cancer. (Pubmed Central) - Oct 28, 2023 Because they are secreted and significantly upregulated in the microenvironment of tumor cells, miRs-100, -10b and -182 are promising circulating biomarkers that can be used to predict or detect therapy responses under CDK inhibition. MiR-10a, miR-15b, miR-21, miR-23a and miR-23c are potential tissue-based biomarkers.
- |||||||||| Orserdu (elacestrant) / Menarini
Review, Journal, Metastases: Elacestrant for ER-Positive HER2-Negative Advanced Breast Cancer. (Pubmed Central) - Oct 27, 2023 Phase 1 and 3 trials showed elacestrant was safe and improved progression-free survival in patients with endocrine receptor 1 (ESR1) mutations who failed cyclin-dependent kinase 4/6 inhibitor (CDK 4/6i) plus 1 prior endocrine therapy compared with standard of care (SOC) (fulvestrant, anastrozole, letrozole, or exemestane monotherapy). Elacestrant is currently being studied in CDK 4/6 inhibitor na
- |||||||||| Ibrance (palbociclib) / Pfizer, Tukysa (tucatinib) / Pfizer
Trial completion, Trial completion date, Combination therapy, Metastases: Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer (clinicaltrials.gov) - Oct 27, 2023 P1/2, N=42, Completed, Elacestrant is currently being studied in CDK 4/6 inhibitor na Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Feb 2023
- |||||||||| letrozole / Generic mfg., capecitabine / Generic mfg.
Journal: Late recurrence of lobular breast carcinoma presented as gastric metastasis. (Pubmed Central) - Oct 26, 2023 The sample showed infiltration by lobular breast carcinoma CK7 (+), CK20 (-), CDX2 (-), GATA3 (+) GCDFP15 (+) RE (+) RP (-) HER2 (-). Treatment with capecitabine was started, with which it continues currently.
- |||||||||| Ibrance (palbociclib) / Pfizer, Keytruda (pembrolizumab) / Merck (MSD)
Enrollment closed: Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer (clinicaltrials.gov) - Oct 26, 2023 P2, N=40, Active, not recruiting, Treatment with capecitabine was started, with which it continues currently. Suspended --> Active, not recruiting
- |||||||||| letrozole / Generic mfg.
Trial completion date, Trial primary completion date, Combination therapy: Study of Letrozole in Recurrent Gliomas (clinicaltrials.gov) - Oct 25, 2023 P1, N=42, Active, not recruiting, Not yet recruiting --> Recruiting Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Sep 2023 --> Sep 2024
- |||||||||| Ibrance (palbociclib) / Pfizer
Journal: Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer. (Pubmed Central) - Oct 22, 2023 Both clinical PFS and OS in the concomitant PPI group were consistently poor in patients receiving endocrine-sensitive and endocrine-resistant treatment. These findings suggest that concomitant use of PPIs with palbociclib may hinder the complete therapeutic benefits of palbociclib in patients with breast cancer.
- |||||||||| Journal, Metastases: Ribociclib-induced visual hallucination in a patient with metastatic breast cancer. (Pubmed Central) - Oct 22, 2023
These findings suggest that concomitant use of PPIs with palbociclib may hinder the complete therapeutic benefits of palbociclib in patients with breast cancer. To our knowledge, this is the first reported case of hallucinations caused by ribociclib; notably, it shows that symptoms may develop in the early stage of treatment.
- |||||||||| Prolia (denosumab) / Amgen, Daiichi Sankyo, letrozole / Generic mfg., Kisqali (ribociclib) / Novartis
Journal, Metastases: Toxic hepatitis in metastatic breast cancer patient using ribociclib and denosumab. (Pubmed Central) - Oct 22, 2023 Since the liver biopsy was toxic hepatitis, it was thought that other drugs used by the patient might cause this toxicity, and a significant decrease was observed in liver values after discontinuation of denosumab. Denosumab-induced liver toxicity is very rare, and there are only a limited number of cases in the literature.
- |||||||||| Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Trial completion date, Trial primary completion date, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Oct 17, 2023 P1/2, N=255, Active, not recruiting, Denosumab-induced liver toxicity is very rare, and there are only a limited number of cases in the literature. Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Nov 2023 --> Nov 2024
- |||||||||| Kisqali (ribociclib) / Novartis
Trial initiation date, Trial primary completion date, Real-world evidence: ADJUVANT WIDER: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (clinicaltrials.gov) - Oct 16, 2023 P3, N=2500, Not yet recruiting, Not yet recruiting --> Recruiting | Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Aug 2023 --> Aug 2024 Initiation date: Sep 2023 --> Jan 2024 | Trial primary completion date: Jun 2030 --> Jul 2028
- |||||||||| letrozole / Generic mfg.
Preclinical, Journal: Comprehensive Analysis of Gut Microbiota Alteration in the Patients and Animal Models with Polycystic Ovary Syndrome. (Pubmed Central) - Oct 12, 2023 The clinical patients and letrozole-induced animal models were determined on PCOS indexes and gut microbiota, and fecal microbiota transplantation (FMT) was conducted...Overall, the results indicate the involvement of gut microbiota in PCOS and its possible alleviation of endocrinal and reproductive dysfunctions through several special bacteria taxa, which can function as the biomarker or potential target for diagnosis and treatment. These results can provide the new insights for treatment and prevention strategies of PCOS.
- |||||||||| letrozole / Generic mfg., everolimus / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer (clinicaltrials.gov) - Oct 10, 2023 P2, N=42, Active, not recruiting, Trial completion date: Sep 2023 --> Dec 2023 | Trial primary completion date: Sep 2023 --> Dec 2023 Trial completion date: Apr 2023 --> Apr 2028 | Trial primary completion date: Apr 2022 --> Apr 2028
- |||||||||| letrozole / Generic mfg.
Journal: NLRP3 Inflammasome-dependent Pathway is Involved in the Pathogenesis of Polycystic Ovary Syndrome. (Pubmed Central) - Oct 10, 2023 Ovarian specimens were collected from mice with polycystic ovarian changes induced by a high-fat diet and letrozole...The RT-qPCR results revealed that the expression levels of GANAB, ALG-5, HSD3B2, ULK1, PTK2B, and Casp7 in KGN cells after NLRP3 overexpression were significantly higher than those in control cells, which was consistent with the RNA-Seq results. Taken together, the NLRP3 inflammasome-dependent pathway is involved in the pathogenesis of PCOS not only by mediating pyroptosis, but also by regulating glycan synthesis, sex hormone synthesis, autophagy, and apoptosis in GCs.
- |||||||||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca, Herceptin (trastuzumab) / Roche
Enrollment open, Trial initiation date: ARIADNE: Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer (clinicaltrials.gov) - Oct 10, 2023 P2, N=370, Recruiting, CC can improve ovulation disorders in rats, and its mechanism is related to the regulation of the secretion of serum hormone and follicular fluid metabolites and the amelioration of multi-metabolic pathways. Not yet recruiting --> Recruiting | Initiation date: Jun 2023 --> Oct 2023
- |||||||||| lerociclib (G1T38) / Walvax, Pepper Bio
Enrollment change, Trial withdrawal, Combination therapy, Metastases: Comparison of Letrozole With Lerociclib Versus Letrozole With Placebo Control in Patients With Advanced/Metastatic or Recurrent, Grade 1 or Grade 2 Endometrial Cancer (clinicaltrials.gov) - Sep 28, 2023 P3, N=0, Withdrawn, Recruiting --> Completed | N=124 --> 4 | Trial completion date: Apr 2024 --> Sep 2023 | Trial primary completion date: Apr 2024 --> Sep 2023 N=320 --> 0 | Active, not recruiting --> Withdrawn
- |||||||||| letrozole / Generic mfg., clomifene citrate / Generic mfg.
Preclinical, Review, Journal: In vitro fertilisation for unexplained subfertility. (Pubmed Central) - Sep 27, 2023 IVF may improve LBR over unstimulated IUI. Data should be interpreted with caution as overall evidence quality was low.
- |||||||||| Herceptin (trastuzumab) / Roche
Preclinical, Journal: Efficacy of copper nanoparticles encapsulated in soya lecithin liposomes in treating breast cancer cells (MCF-7) in vitro. (Pubmed Central) - Sep 25, 2023 There are several drugs approved by FDA used in breast cancer treatment like Cyclophosphamide, Doxorubicin Hydrochloride, Femara, Herceptin, etc. Each has several side effects as well as treatment, which limits the use of drugs due to heart failure, pulmonary dysfunction, or immunodeficiency...Some drugs have been approved for use in cancer treatment under the concept of drug delivery, such as Doxil (liposomal loaded doxorubicin)...The cytotoxicity assay showed that the IC of Cu/SLP is smaller than that of free CuNPs. These results give clear evidence of the efficacy of using the combined Cu/SLP rather than CuNPs alone as a model drug carrier prepared from plant origin against cancer, both medically and economically.
|